

1 [Settlement of Lawsuit - Allergan Finance, LLC and Allergan Limited - City to Receive
2 \$12,916,274 Over 5 Years]

3 Ordinance authorizing settlement of the lawsuit filed by the City and County of San
4 Francisco and the People of the State of California against Allergan Finance, LLC (f/k/a
5 Actavis, Inc., which, in turn, was f/k/a Watson Pharmaceuticals, Inc.) and Allergan
6 Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc) for \$12,916,274 (the City
7 to be paid \$10,156,889 over 5 years, the City's outside counsel to be paid \$1,585,179,
8 and the City Attorney's Office to be paid \$1,174,206); directing the Controller to allocate
9 funds to the City Attorney's Office as provided in the settlement agreement; the lawsuit
10 was filed on December 18, 2018, in the United States District Court for the Northern
11 District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of
12 San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard
13 S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler
14 Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of
15 Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon,
16 Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo
17 International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen
18 Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC,
19 Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson
20 Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.,
21 AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the
22 lawsuit involves allegations that the Allergan defendants created a public nuisance and
23 violated the Unfair Competition Law by falsely and misleadingly marketing opioids as
24 safer than they actually are and distributing increasingly large volumes of opioids in
25 and around San Francisco despite knowledge of the growing epidemic caused by

1 **opioid misuse, and by failing to prevent and report suspicious opioid orders as**
2 **required by state and federal law.**

3 Be it ordained by the People of the City and County of San Francisco:
4

5 Section 1. Pursuant to Charter Section 6.102(5), the Board of Supervisors hereby
6 authorizes the City Attorney to settle the action entitled The City and County of San Francisco
7 and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan
8 D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler,
9 Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler
10 Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd.,
11 Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo
12 Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt
13 Plc, Mallinckrodt LLC, Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a
14 Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson
15 Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson
16 Corporation, the United States District Court for the Northern District of California, Case No.
17 3:18-cv-7591-CRB-JSC by the payment of \$12,916,274 (the City to be paid \$10,156,889 over
18 5 years, the City's outside counsel to be paid \$1,585,179, and the City Attorney's Office to be
19 paid \$1,174,206) by Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn, was f/k/a
20 Watson Pharmaceuticals, Inc.) and Allergan Limited (f/k/a Allergan plc, which, in turn, was
21 f/k/a Actavis plc). The lawsuit involves allegations that the Allergan defendants created a
22 public nuisance and violated the Unfair Competition Law by falsely and misleadingly
23 marketing opioids as safer than they actually are and distributing increasingly large volumes
24 of opioids in and around San Francisco despite knowledge of the growing epidemic caused by
25

1 opioid misuse, and by failing to prevent and report suspicious opioid orders as required by
2 state and federal law.

3 Section 2. The above-named action was filed in the United States District Court for the
4 Northern District of California on December 18, 2018, and the following parties were named in
5 the lawsuit: The City and County of San Francisco and the People of the State of California,
6 as plaintiffs; Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company, Inc.;
7 Rhodes Pharmaceuticals L.P.; Richard S. Sackler; Jonathan D. Sackler; Mortimer D.A.
8 Sackler, Kathe A. Sackler; Ilene Sackler Lefcourt; Beverly Sackler; Theresa Sackler; David A.
9 Sackler; Trust for the Benefit of the Raymond Sackler Family; Allergan Plc f/k/a Actavis Plc;
10 Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.; Allergan Sales,
11 LLC; Allergan USA, Inc.; Watson Laboratories, Inc.; Warner Chilcott Company, LLC; Actavis
12 Pharma, Inc. f/k/a Watson Pharma, Inc.; Actavis South Atlantic LLC; Actavis Elizabeth LLC;
13 Actavis Mid Atlantic LLC; Actavis Totowa LLC; Actavis LLC; Actavis Kadian LLC; Actavis
14 Laboratories UT, Inc. f/k/a Watson Laboratories, Inc.-Salt Lake City; Actavis Laboratories FL,
15 Inc. f/k/a Watson Laboratories, Inc.-Florida; Teva Pharmaceuticals USA, Inc.; Teva
16 Pharmaceutical Industries Ltd.; Cephalon, Inc.; Johnson & Johnson; Janssen
17 Pharmaceuticals, Inc.; Noramco, Inc.; Ortho-Mcneil-Janssen Pharmaceuticals, Inc.; Janssen
18 Pharmaceutica, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Par
19 Pharmaceuticals, Inc.; Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical
20 Holdings, Inc.; Endo International Plc; Insys Therapeutics, Inc.; Mallinckrodt Plc; Mallinckrodt
21 LLC; Specgx LLC; AmerisourceBergen Drug Corporation; Anda, Inc.; Cardinal Health, Inc.;
22 McKesson Corporation; and Walgreen Co. as defendants.

23 Section 3. The Controller is hereby authorized and directed to allocate the payment of
24 funds for the reimbursement of attorneys' fees to the City Attorney's Office in the amount
25 provided in the settlement agreement.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

APPROVED AS TO FORM:
DAVID CHIU, City Attorney

By: /s/ Sara J. Eisenberg
SARA J. EISENBERG
Chief of Complex and Affirmative Litigation

n:\cpu\li2023\190034\01657178.docx



City and County of San Francisco

Tails Ordinance

City Hall
1 Dr. Carlton B. Goodlett Place
San Francisco, CA 94102-4689

File Number: 230688

Date Passed: September 12, 2023

Ordinance authorizing settlement of the lawsuit filed by the City and County of San Francisco and the People of the State of California against Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn, was f/k/a Watson Pharmaceuticals, Inc.) and Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc) for \$12,916,274 (the City to be paid \$10,156,889 over 5 years, the City's outside counsel to be paid \$1,585,179, and the City Attorney's Office to be paid \$1,174,206); directing the Controller to allocate funds to the City Attorney's Office as provided in the settlement agreement; the lawsuit was filed on December 18, 2018, in the United States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the lawsuit involves allegations that the Allergan defendants created a public nuisance and violated the Unfair Competition Law by falsely and misleadingly marketing opioids as safer than they actually are and distributing increasingly large volumes of opioids in and around San Francisco despite knowledge of the growing epidemic caused by opioid misuse, and by failing to prevent and report suspicious opioid orders as required by state and federal law.

July 20, 2023 Government Audit and Oversight Committee - RECOMMENDED

September 05, 2023 Board of Supervisors - PASSED ON FIRST READING


Ayes: 11 - Chan, Dorsey, Engardio, Mandelman, Melgar, Peskin, Preston, Ronen, Safai, Stefani and Walton

September 12, 2023 Board of Supervisors - FINALLY PASSED


Ayes: 11 - Chan, Dorsey, Engardio, Mandelman, Melgar, Peskin, Preston, Ronen, Safai, Stefani and Walton

File No. 230688


I hereby certify that the foregoing
Ordinance was FINALLY PASSED on
9/12/2023 by the Board of Supervisors of the
City and County of San Francisco.



Angela Calvillo
Clerk of the Board



London N. Breed
Mayor



Date Approved